INTERVENTIONAL VASCULAR CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

21 Feb 2018

First Patient in Latin America Receives TheraSphere® Radioembolisation Treatment

February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.

5 Oct 2017

BTG plc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

25 Jul 2017

Vancouver’s EVA Vein Care Now Offers New Varicose Vein Treatment

Minimally Invasive Non-Surgical Procedure Now Available in Time for Summer

26 Jan 2017

New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians

BTG International Canada Inc., part of global specialist healthcare company BTG (LSE: BTG), today announced the Canadian commercial launch of Varithena™ (polidocanol injectable foam), a drug/device combination product used to treat varicose veins.

26 Jan 2017

Nouveau traitement des varices offrant une intervention non chirurgicale à effraction minimale pour les Canadiens

BTG International Canada Inc., qui fait partie de BTG, une entreprise internationale de soins de santé spécialisés (LSE : BTG), a annoncé aujourd’hui le lancement sur le marché canadien de Varithena™ (mousse injectable à base de polidocanol), une combinaison de médicament et d’appareil utilisé pour traiter les varices.

9 Jan 2017

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® system.

BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system.

5 Dec 2016

PneumRx® Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx® Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

5 Dec 2016

Le Canada, premier pays à bénéficier d’une nouvelle option de traitement contre le cancer du foie

Les microsphères radio-opaques à élution médicamenteuse DC Bead LUMIMC offrent aux radiologistes interventionnels du Canada un traitement de nouvelle génération pour les patients atteints d’un cancer du foie

14 Oct 2016

BTG and Mirada Medical announce CE Mark Certification for Simplicit Y90 dosimetry software in Europe

New easy-to-use software designed to improve the planning of Y90 selective internal radiation therapy (SIRT) treatment for patients with liver cancer

BTG plc (LSE: BTG), an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit Y90™ dosimetry software, designed to optimise the planning of Y90 selective internal radiation therapy (SIRT) and facilitate personalised treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit Y90™ in Canada.